The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has been 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
TriHaz Solutions Opens New Chattanooga, Tennessee Facility to Expand Regulated Medical Waste Services Across the Southeast
Chattanooga, TN – February 17, 2026 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility located at 4120 S Creek Rd, Chattanooga, TN 37406. This expansion strengthens TriHaz’s ability to serve healthcare facilities, laboratories, and clinical operations throughout Chattanooga and surrounding Tennessee markets with reliable and fully compliant medical waste disposal services. [Read more…]
Who Is CryoHoldco? Latin America’s Largest Cord Blood Bank
CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and the fifth largest cord blood banks globally. CryoHoldco is also many times larger than any other stem cell bank in Latin America, with over 400,000 stem cell units in storage.
Cynata Introduces Critical Innovation into MSC Manufacturing
In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.
In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]
An Expert’s Perspective on Accelerated Pathways for Cell Therapy Approvals
Over the past few years, the regulatory landscape for cell therapy development has grown increasingly complex. There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. While the possibility for accelerated commercialization has resulted from these changes, substantial complexity has also been introduced, making it a more elaborate process to move cell therapy products from “bench to bedside.”
In the interview with Yaron Ramati, Director of Regulatory Affairs at Pluristem Therapeutics, we get an expert’s perspective on how the regulatory environment has changed and new opportunities that exist for bringing cell therapy products through the clinical trial process and into the global marketplace. [Read more…]
- 1
- 2
- 3
- 4
- Next Page »